Polyrizon's moving forward with expected 2025 clinical trial - entered manufacturing agreement for its pl-14 allergy blocker

The engagement with an eu-based gmp manufacturing facility enables timely production and preparation for clinical trial. the eu-based gmp manufacturer has large-scale commercial production capabilities, to support polyrizon in future commercialization efforts
PLRZ Ratings Summary
PLRZ Quant Ranking